Amgen attorneys win a megablockbuster patent case, dealing Novartis a severe setback on biosimilars play
Don’t bet against Amgen attorneys.
That’s what Umer Raffat’s old mentor Mark Schoenbaum told the Evercore ISI analyst when he was prepping for a recent deep dive on Amgen’s Enbrel.
Like other classic remarks about Amgen’s litigious nature, it was dead on.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.